SPONSOR
Ranok Therapeutics (Hangzhou) Co., Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 1, Phase 2
Conditions studied: KRAS G12D MutationsPancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid TumorDLBCL
Ranok Therapeutics (Hangzhou) Co., Ltd. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including KRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor, DLBCL.
The trial portfolio spans Phase 2, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Ranok Therapeutics (Hangzhou) Co., Ltd.
How many clinical trials has Ranok Therapeutics (Hangzhou) Co., Ltd. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Ranok Therapeutics (Hangzhou) Co., Ltd., of which 2 are actively recruiting participants. These trials cover conditions including KRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Ranok Therapeutics (Hangzhou) Co., Ltd. research focus on?
Ranok Therapeutics (Hangzhou) Co., Ltd. clinical trials span KRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor, DLBCL. The research pipeline includes Phase 2, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Ranok Therapeutics (Hangzhou) Co., Ltd. clinical trial?
To participate in a Ranok Therapeutics (Hangzhou) Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Ranok Therapeutics (Hangzhou) Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Ranok Therapeutics (Hangzhou) Co., Ltd.
NCT07303465 Phase 2
Recruiting
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
KRAS G12D Mutations
NCT05487170 Phase 1, Phase 2
Recruiting
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Advanced Solid Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology